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a b s t r a c t
In 2004, the United States Preventive Services Task Force (USPSTF) gave testicular cancer (TCa) screening a ‘D’
recommendation, discouraging the use of this preventive service. The USPSTF suggested that screening, inclusive
of testicular self-examination (TSE) and clinician examination, does not reduce TCa mortality rates and that the
high risk of false positives could serve as a detriment to patient quality of life. Others suggests that TCa screening
is ineffective at detecting early-stage cases of TCa and readily highlights a lack of empirical evidence demonstrating said efﬁcacy. These assertions, however, stand in stark contrast to the widely held support of TCa screening
among practicing public health professionals, advocacy groups, and clinicians.
In this present study, a review was conducted of the methods and processes used by the USPSTF in their 2011
reafﬁrmation of the ‘D’ grade recommendation. The evidence base and commentary offered as to why TSE, as
part of the overall recommendation for TCa screening, was given a ‘D’ grade were analyzed for logical reasoning
and methodological rigor.
Considering the methodological ﬂaws and the veritable lack of evidence needed to grant a conclusive recommendation, the question is raised if the current ‘D’ grade for TCa screening (i.e. discourage the use of said service)
should be changed to an ‘I’ statement (i.e. the balance of beneﬁts and harms is indeterminate). Therefore the purpose of this paper is to present the evidence of TCa screening in the context of efﬁcacy and prevention in order for
the ﬁeld to reassess its relative value.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
The United States Preventive Services Task Force (USPSTF, 2004;
2011) suggests that there is a lack of available evidence demonstrating
how routine testicular cancer (TCa) screening (including both testicular
self-examination [TSE] and clinician examination) has greater yield
and/or accuracy for detecting TCa at more curable stages (USPSTF,
2011). The Task Force also claims that, generally, TCa is N 90% curable
and that TCa screening is unlikely to offer meaningful health beneﬁts.
One adverse outcome readily offered as evidence that TCa screening
(i.e. TSE) should not be recommended is the potential onset of anxiety
associated with a false-positive result. Essentially, according to the
USPSTF, among others (e.g. Lin and Sharangpani, 2010), TSE and clinician examinations have limited value. This position, however, is
grounded in limited evidence and fails to take into account the potential
beneﬁts of TCa screening.
Incidence rates of TCa are rising among the 15 to 54 year-old demographic, but primarily affect those under the age of 40 (Kennett et al.,
2014). Howlader et al. (2013) indicates that TCa cases have been rising
~1% each year in the past decade. As there are few known risk factors for
TCa outside of age (Znaor et al., 2014), cryptorchidism (Lip et al., 2013),
or family history of the disease (Kharazmi et al., 2015), it is wise to operate under the assumption that all males are at-risk for developing the
disease. Those males who lay claim to one or more of the aforementioned risk-factors could be labeled ‘high-risk’, but the relationship between TCa manifestation and said factors remain spurious at best due
to the lack of research conducted highlighting those associations.
It is the collective wisdom of these authors that all males receive
multifactorial beneﬁts from regular TSE performance, inclusive of decreased mortality from the disease (see Rovito et al., 2015). The issue,
however, for both sides of this debate, but more so serving as the onus
for the anti-TSE camp, that when speaking exclusively about TCa mortality reduction, there are zero studies conducted among asymptomatic
males demonstrating the harms and/or beneﬁts received from testicular
examination, either clinician or self-examination. In essence, the evidence is insufﬁcient to point one way or the other. Hence, the current
D-grade recommendation, according to the deﬁnitions used by the
Task Force themselves, is erroneously granted to TSE. Due to the dearth
of evidence between physical examination of testicles as a preventive
measure to decrease TCa mortality, it is more appropriate to grant an
I-statement recommendation.
The following discussion will highlight the spurious nature of the
data used by the USPSTF to discourage TCa screening, as well as the inconsistencies in methodological rigor used to create its current ‘D’ grade
recommendation. As the criteria used to create ratings are limited in
scope with some having little, if any, relevance in the decision-making
process to determine TCa screening's worth, these authors advocate
for a reassessment of the current methodology used when creating recommendations in the absence of solid evidence. Finally, these authors
question the appropriateness of the USPSTF (2011) ‘D’ grade for TCa
screening and lend support for Rovito (2016) argument for the inclusion of TSE in a standard of care as the potential harms associated
with the ‘D’ grade are a cause for concern for male lifespan health.
1.1. Overview of the recommendation process and current support
Recommendations made by the USPSTF (2011) are based on explicit
criteria. An independent panel of experts in primary care and prevention systematically review the available evidence of effectiveness on a
particular topic and develop recommendations for clinical preventive
services accordingly (Agency of Healthcare Research and Quality,
2012). Other experts in the ﬁeld outside of primary care are invited to
provide peer review of existing evidence summaries and draft recommendations (Siu et al., 2015). USPSTF panels tend to be conservative
in their recommendation statements, relying solely on available scientiﬁc evidence. Their approach differs from other bodies that develop

clinical practice guidelines (CPGs), which may rely on expert opinion
and clinical judgment in the absence of randomized controlled trials
(RCTs) (Goolsby, 2002).
One of the main challenges in developing recommendations is deciding which position to take when the evidence is inadequate and lacking, as is the case for TCa screening, and more speciﬁcally, TSE. RCTs are
generally regarded as the strongest evidence base for providing an intervention by the USPSTF (2011). Yet, even the Task Force acknowledges that this standard of evidence is unattainable for a majority of
clinical preventive services. Recognizing this limitation, non-RCT study
designs also are included in the evidence base used by the USPSTF
(Petitti et al., 2009). The USPSTF (2011) considers indirect evidence in
such cases where a ‘chain of evidence’ is created within an analytic
framework to inform the recommendation (Petitti et al., 2009).
Some have advocated that the Task Force provide ‘clinical options’
(especially if the harms and costs with performing a particular service
are minimal) or that services, which have not been adequately studied,
should not be recommended (Woolf and Atkins, 2001). Some suggest
that a neutral stance should be taken (meaning not recommending for
or against a service) until better evidence is available or that those
who are deemed high-risk should be informed of the beneﬁts of
performing regular TSE (Woolf and Atkins, 2001; American Urological
Association [AUA], 2014). Others explicitly state (i.e. the Society for
Adolescent Health and Medicine, 2012) their support for TCa screening
or suggest that identiﬁed high-risk males (i.e. Caucasian race, being
between the ages of 15–40, family history of the disease, and/or the
occurrence of cryptorchidism) should ‘seriously’ consider performing
monthly exams (ACS, 2015).

1.2. Past and present USPSTF recommendations for TCa screening
Calonge (2005) states that in 1996, the USPSTF found that existing
evidence to recommend either for or against routine screening for TCa
was insufﬁcient as it pertains to asymptomatic men. TCa screening
was given a ‘C’ grade, indicating the reviewing body was not in a position to recommend promoting the behavior or not, thus leaving the decision to the patient and provider. The reviewers included a caveat that
for males who were deemed high-risk for TCa, discussions about screening (either TSE or physician exams) can be carried out. In other words,
there was insufﬁcient evidence to fully commit to a more positive or
more negative TSE recommendation. If, however, a practitioner identiﬁes a male at high risk for developing TCa, then a conversation about
TSE is permissible, which is much akin to the AUA's (2014) current
position.
The USPSTF (2013) grade deﬁnitions have since changed, where a ‘C’
grade currently indicates that the service should be offered to select patients depending on individual circumstances. Consequently, the
USPSTF reassessed the ‘C’ grade for TCa screening in 2004 and came to
the conclusion that they found at least fair evidence that it (i.e. TSE) is
ineffective and that the harms outweigh the beneﬁts. They speciﬁcally
argued that no evidence has been produced from appropriate study designs (i.e. RCTs) demonstrating a signiﬁcant decrease in TCa mortality
stemming from the promotion of screening among asymptomatic
males. They gave TCa screening a ‘D’ grade, which is deﬁned as “moderate or high certainty that the service has no net beneﬁt and that the
harms outweigh the beneﬁts” (USPSTF, 2013).
A 2008 reafﬁrmation request brought about Lin and Sharangpani's
(2010) rubberstamping of the TCa screening ‘D’ grade. The authors
based their decision upon the high cure rates of TCa (even in later stages
of the disease), the potential for false-positive anxiety, the lack of
evidence demonstrating TCa screening's effectiveness in reducing
mortality, and the potential of increasing costs due to conﬁrmatory
procedures (i.e. ultrasound, biopsies, etc.). In 2011, the USPSTF reissued
the ‘D’ grade for the provision of TCa screening by self- or clinician
examination.
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2. Inconsistencies in logic, language, and methodology
Upon careful consideration of the arguments provided by the
USPSTF (2011), these authors suggest that the Task Force's rationale is
ﬂawed, and therefore, insufﬁcient to offer a conclusive recommendation
concerning TCa screening. The following is an overview of the logic provided by the Task Force and subsequent gaps in its foundational
arguments.
2.1. Overview of the TCa screening recommendation search criteria
The USPSTF presented its ﬁnal evidence review for TCa screening in
2011. The reafﬁrmation update was based on a search for new, highquality studies that may have potentially changed the previous recommendation. However, in conducting their literature search, Lin and
Sharangpani (2010), discovered that no such studies met the inclusion
criteria to address the primary questions assessing the beneﬁts and
harms of screening asymptomatic men for TCa. Of the 113 potentially
relevant articles that were initially identiﬁed, 99 were excluded on
title, leaving 14 articles that underwent an abstract review. The most
common reason for exclusion was that testing or interventions were
not performed in asymptomatic populations. The remaining three articles (two of which were not about screening) reached the full-text review stage (Lin and Sharangpani, 2010). This lack of evidence was also
highlighted by Ilic and Misso (2011) who suggest that no published
RCTs exist evaluating the effectiveness TCa screening. In summary, the
Task Force failed to identify any sources that could lend conclusive evidence to support or not support TCa screening as deﬁned by their own
‘D’ rating criteria. The current recommendation against TCa screening
is essentially based on three arbitrarily chosen citations with little rationale to explain the process.
This lack of transparency and accountability has been noted in other
recommendations from the USPSTF, such as prostate cancer screening
(Kaffenberger and Penson, 2014). Critics of the USPSTF evidence review
and recommendation process in regard to prostate cancer point to critical misinterpretations of key evidence regarding beneﬁts of screening
and selective publications that overstate the harms (Cooperberg
2014). With zero studies that explicitly point to either the harms or beneﬁts of TCa screening, the current ‘D’ grade is an unjustiﬁed overstatement of the potential harms, with little consideration to the various
beneﬁts of self- or clinician screening.
2.2. A lack of evidence
The USPSTF (2011) indicates that no evidence exists indicating that
TCa screening would improve health outcomes. As indicated previously,
however, no hard evidence exists showcasing harms associated with
TSE or clinician examination, at least to the knowledge of these authors.
Interestingly, the Task Force themselves, as well as supporters of the ‘D’
grade, actually admit to the lack of evidence showcasing not just TCa
screening's beneﬁts (their fulcrum argument), but also its harms.
For example, Lin and Sharangpani (2010) indicate that they failed to
identify any evidence directly discussing TCa screening harms and beneﬁts, while the American Cancer Society (2015) states that the lack of
evidence prevents them from forming any concrete recommendation
about TCa screening, although, as discussed prior, they list on their
website that those deemed high risk should consider performing
monthly exams. The National Cancer Institute (2015), which distributes
information on how to perform TSE, suggests that TCa screening harms
are poorly quantiﬁed and that there is no available evidence that allows
the ﬁeld to determine TCa screening's effectiveness in reducing mortality rates associated with the disease. The USPSTF (2011) itself stated
that the available evidence was inadequate to determine whether
asymptomatic patient TCa screening has greater yield or accuracy for
detecting TCa at more curable stages.
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In essence, zero new evidence was found that examined either the
harms or beneﬁts of screening, yet a ‘D’ grade was offered, suggesting
that the evidence was fair enough to warrant a conclusive decision to
not support TCa screening (further detail on this is offered in the next
section). This logic is obviously ﬂawed. Although the primary outcomes
used to build a case against TCa screening are the lack of evidence showcasing the effect of screening upon lowering TCa mortality and its potential to increase anxiety stemming from false-positives, there is no
evidence measuring either of these variables to even speculate on any
conclusion, let alone offering one.
At this point, the lack of evidence would suggest that there is no
sound foundation upon which a recommendation can be based. Despite
this, the reafﬁrmation update cited the three studies in establishing
their recommendation. To assume that lack of evidence of effectiveness of TCa screening equates to the evidence of absence of
effectiveness, according to these authors, is dangerous. CPGs and
recommendations are only as good as the evidence on which they
are based and insufﬁcient evidence often results in weak recommendations (Francis 2013).

2.3. ‘Fair’ and ‘sufﬁcient’ evidence
The USPSTF (2011) stated that fair evidence exists demonstrating
the ineffectiveness of TCa screening and that the harms outweigh the
beneﬁts of performing the behavior. This statement, as mentioned previously, was made despite their own admission on the inadequacy of
available evidence to conclusively determine if TCa screening is beneﬁcial or harmful.
Calonge (2005) indicates that the USPSTF's deﬁnition of ‘fair evidence’ is:
“Evidence is sufﬁcient to determine effects on health outcomes, but the
strength of the evidence is limited by the number, quality, or consistency
of the individual studies, generalizability to routine practice, or indirect
nature of the evidence on health outcomes.” (p. 2069–2070)
An issue arises, however, as to the use of the word sufﬁcient. There is a
sense of ambiguity with the use of that word pertaining to the threshold
needed to make a recommendation. Some questions that arise are: Is the
USPSTF's operational deﬁnition of sufﬁciency similar to other professional
bodies in the ﬁeld? At what point was the evidence insufﬁcient and at
what point was the evidence sufﬁcient to make the decision? In other
words, what are the criteria for insufﬁciency? The USPSTF refrains from
providing any clarity on the threshold for deeming something sufﬁcient,
therefore casting doubt on the objectivity of the term. The Task Force, in
summary, suggests the existence of sufﬁcient evidence, which leads
them to conclude that fair evidence exists on TCa screening's ineffectiveness, despite their admission that there is an absence of evidence that can
lead them to determine if it is harmful or beneﬁcial.
Highlighting the above ﬂawed rationale further, in their 2009 update
on methods regarding insufﬁcient evidence, the Task Force recognized
limitations with using such language. The statement ‘evidence is insufﬁcient’ was characterized as ‘useless’ or ‘worse than useless’ by clinicians and professional societies who expressed the need for better
guidance in recommendations (Petitti et al., 2009). Yet, the deﬁnition
of this term remains vague at best.
These authors posit that if pro-TSE advocates enact this clause of sufﬁcient evidence, they would emerge as having the superior argument.
The historical demonstration of TSE's beneﬁt (see Morman, 2000;
Ward et al., 2005; McGilligan et al., 2009; Wanzer et al., 2014,
Thornton, 2016, among others) compared to the Task Force and others,
who, again, have yet to produce a solid piece of evidence sufﬁciently
demonstrating TSE's harms, is essentially a lopsided debate. The available evidence is exclusively rooted in demonstrating TSE's beneﬁt as
no evidence exists on its harms.
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2.4. Outcomes used to determine TCa Screening's Worth: mortality, anxiety,
and costs
The USPSTF (2011) states that males typically detect TCa unintentionally or through self/partner examination. Other research suggests
that the best outcomes for TCa treatment stem from cases treated in earlier stages of the disease (see Saab et al., 2014; Gilligan, 2015; Ozturk
et al., 2015). It would therefore be logical to assume that TSE or clinician
examination promotes optimal wellness within this population. The rationale of the USPSTF (2011), however, is rooted in the notion that
males should not undergo any type of physical examination to detect
TCa due to the high probability of cure and prevention of death. The
USPSTF (2011) essentially suggests that males should not be screened
for TCa. If males are possibly diagnosed with the disease, it is very treatable and the individual will (most likely) live. This line of reasoning is
troubling as it is essentially a gamble on an individual's expected rate
of recovery and response to treatment. As an aside, no studies exist testing the effectiveness of TCa screening upon reducing TCa mortality, yet
the Task Force continues to use this as a primary argument against the
promotion of TCa screening.
The Task Force and the supporters of TCa screening's apparent harmfulness (beyond their assertion that TCa screening does not reduce mortality), including Casey et al. (2011), continue to suggest that anxiety
may manifest in the face of a false-positive screening. They fail, yet
again, to produce any such evidence supporting their claim. These authors do not doubt that certain levels of anxiety would result from a
false-positive TSE as similar trends have been historically observed
with false-positive test results. For example, Fylan (1998) discusses
the issue regarding abnormal smears in cervical cancer screening,
Nelson (2013) discusses it from the standpoint of breast cancer screening, and Brown, Djimeu, and Cameron (2014) present a discussion on
HIV self-tests and possible adverse psychosocial effects from falsepositive results. However, again, a thread woven throughout the majority of such studies and statements suggesting false-positive anxiety is a
reason to not perform self-exams of any kind is that little, if any at all,
evidence exists to make such a claim.
A recent review (Saab et al., 2016) found that highlighting the high
cure rate of TCa can actually help overcome cancer-related anxiety.
This also may serve as part of the counter-argument to the USPSTF
(2011) and others where teaching males about TCa and TSE to increase
knowledge and awareness of the disease, preventive measures, and
treatments would actually decrease anxiety (see also Rovito et al.,
2015). Another commentary (Rovito, 2016) provides more insight on
the illogical use of anxiety as a central point in the argument against
TCa screening.
One outcome the Task Force fails to consider in its rating of TCa
screening is the signiﬁcant impact on the quality of life and risk of adverse mental health outcomes related to late-stage diagnosis. Longterm health implications of more invasive and toxic treatments during
late-stages cases (e.g. chemotherapy, radiation, etc.), previously noted,
are discussed by Gilligan (2015). The authors indicate that later-stage
cases treated with chemotherapy experience a signiﬁcantly worse quality of life and manifest higher frequencies of adverse mental health outcomes as compared to their counterparts diagnosed early in the staging
process.
Finally, in regards to costs associated with TCa screening, aside from
the typical costs associated with a doctor's appointment, performing
this service is virtually free. These authors advocate that if males were
adequately informed on what to screen for and how to properly palpate
their testicles, the issue of unnecessary doctor's appointments to conﬁrm a false-positive would be assuaged signiﬁcantly. However, if we
were to recognize the idea that males will ﬂood clinician ofﬁces with
concerns of lumps on their testicles and almost all of them being falsepositives, Aberger et al. (2014) offer a comprehensive discussion on
cost–beneﬁt analysis on the topic, essentially concluding that the costs
associated with the previous assertion are far outweighed by just one

late-stage TCa diagnosis treatment. Although we trumpet this ﬁnding
as a very important data point in defense of promoting TSE, the Task
Force does not use this is their rubric to judge TSE's usefulness.
These authors caution the ﬁeld on the limitations of using TCa mortality as the primary outcome to determine TCa screening's worth as it
may lose sight of survivorship and lifespan health post-diagnosis. In
other words, the morbidity of the disease and treatments are not
being considered in this primary outcome. This notion supports a growing body of research beginning to challenge survivorships' supremacy as
the ultimate goal for determining TCa screening's beneﬁt (see Rovito
et al., 2015; Ozturk et al., 2015).
If males did not undergo the various forms of physical examination
(TSE, partner, and/or physician), it logically implies that most, if not all
cases (theoretically speaking, at least), would probably not be diagnosed until the disease is metastatic and produces other overt symptoms. Therefore, not recommending that TCa screening should be
offered as a preventive service, whether by clinician or self-examination,
is irresponsible and fails to take into account the harms of not screening,
which far outweigh the potential harms associated with screening.
In summary, the USPSTF (2011) argues that since the disease is so
curable that it justiﬁes a reason not to screen. Again, morbidity of chemotherapy and major abdominal, chest, and brain surgery is missed
with this argument. The Task Force also argues that because TCa does
not have a high incidence, screening will lead to over treatment and investigation. The cost effectiveness argument has been investigated by
Aberger et al. (2014), who indicate that evaluation is possibly costeffective compared with treatment of one missed metastatic disease. Finally, the notion that small, early-detected testicular masses may become metastatic already at presentation (therefore offering no beneﬁt
to the patient) is a moot argument as there is no evidence to support
this, and most other, claims of harm resulting from TCa screening.
3. Conclusion
3.1. In support of TCa screening
Due to the insidious, and often undetectable, nature of cancer (TCa
notwithstanding), prompt identiﬁcation and treatment is warranted.
Self-screening is an effective means to identify certain forms of cancer
given that an individual is most sensitive to their own anatomy and
physiology and changes/anomalies. Given correct information,
practice-based skills, and consistent application of these skills in terms
of self-examination, TCa screening has the potential to further personal
health in males (Rovito et al., 2015).
Often absent in the discussion of TCa screening (i.e. TSE), most notably in the USPSTF (2011) recommendation, are the other beneﬁts of
self-exams, particularly if performed correctly. For example, TSE can
act to familiarize a man with his body where he becomes more sensitive
in noting anomalies such as physical and structural changes (e.g.
bumps, lumps, changes in consistencies) and functional issues, such as
increased or decreased abilities. Moreover, familiarity also may create
a sense of body competence and ‘ownership’ of one's body possibly
leading to a greater likelihood and comfort in reporting and having a dialog with one's healthcare provider (Rovito et al., 2015). The latter
might be equated to an ‘educated consumer’ model.
The public health implications of discouraging TCa screening range
far beyond simple cancer detection, as previously noted. At the very
least, TCa screening can improve male health literacy in terms of familiarity with his body and possibly improving patient-provider communication. The latter statement is notable as research suggests males are
consistently and signiﬁcantly less likely to engage in healthcare
whether for preventative or palliative reasons (Addis and Mahalik,
2003; Leone and Rovito, 2013; Marcell et al., 2015).
Additionally, the age at which TSE is introduced and discussed
(likely in a male's teenage years or early 20s) can help set precedence
for positive engagements with the healthcare system and one's provider

M.J. Rovito et al. / Preventive Medicine Reports 3 (2016) 361–366

(see Dube et al., 2005, for a similar discussion on prostate cancer screening). Discouraging TCa screening via a ‘D’ grade versus an ‘I’ statement
limits the practical utility of TSE or clinician examination, or any selfcare initiative for that matter. Creating a positive experience through
teaching males the value and skills to care for one's body, at least in
these authors' collective opinions, carry greater value and long-term
beneﬁts than the USPSTF ‘D’ grade affords.
3.2. A call for action: changing the current TCa screening recommendation
from ‘D’ to ‘I’
The main question of interest to the Task Force of whether a preventive service “works” has evolved in recent years to a more sophisticated
approach that considers the level of beneﬁt, the trade-off between
harms and beneﬁts, and individual patient and clinical preferences of
a particular service (Woolf and Atkins, 2001). However, in the case of
TCa screening, the methodological rigor used to produce the evidence
to justify the USPSTF's ‘D’ rating, as well as its reafﬁrmation, is questionable at best.
Considering the recent work on the cost-effectiveness of TSE and clinician exams, the broad support TCa screening receives in the ﬁeld, and
its versatility to tending to other health concerns beyond cancer, a more
concerted effort to changing the current rating is warranted. In other
words, with insufﬁcient evidence arguing either for or against
recommending TCa screening among asymptomatic males, further research, particularly RCTs, are needed before a deﬁnitive and conclusive
recommendation can be asserted.
The USPSTF has received criticism from clinicians about the frequency of ‘I’ statements in the past and the need for deﬁnitive guidance
on preventive services. These concerns resulted in the development of a
strategy on behalf of the USPSTF, to address the confusion created by the
language in ‘I’ statements (Petitti et al., 2009). An ‘I’ statement does not
provide clear guidance to practicing clinicians who do not have the luxury of waiting for more evidence to support or negate a certain recommendation and must make decisions at the point of care. In the case of
TCa screening, however, a ‘D’ grade essentially limits its full appreciation
and application beyond simple detection and treatment of TCa. These
authors, therefore, advocate for a robust and continued discussion
concerning the holistic value of TCa screening, particularly in terms of
how it has a multifaceted potential value in positively impacting male
health across the lifespan.
Guirguis-Blake et al. (2007) indicate that the USPSTF aims to “reﬁne
and advance its methodology” (p. 122). Therefore, it is strongly suggested that the USPSTF to reexamine the relative value of TCa screening
(TSE and clinician exams) in light of the methodological and logical
ﬂaws present in the decision-making process of granting the procedure
a ‘D’ grade. These authors suggest a reclassiﬁcation from a ‘D’ grade to an
‘I’ statement as an appropriate next step until more evidence is offered
in order to inform future evaluations and recommendations.
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